New IHE publication on the valuation of and payment for advanced therapy medicinal products (ATMP)

Advanced Therapy Medicinal Products (ATMP) is a new class of drugs in the EU that includes medical products using gene therapy, cell therapy or tissue engineering. Several of these therapies can be expected to lead to elimination of symptoms or disease activity in severely ill patients and thus create long-lasting positive effects on both health and healthcare costs. In the near future, a breakthrough is expected for ATMP.

The purpose of this study is to prepare proposals for new methods for analyzing the value of curative drug treatments, and to give suggestions for financing and payment for curative therapies in a health care system characterized by public budgets.

Download the report (pdf) and read the english summary

Please cite this report as:
Persson U, Olofsson S, Althin R & Fridhammar A. Värdering och betalning för avancerade terapiläkemedel (ATMP). IHE Rapport 2019:1, IHE: Lund, Sverige.